Quetiapine is a novel antipsychotic drug, showing higher activity and fewer side effects than the classical antypsychotic agents. 11-(1-Piperazinyl)dibenzo[b,f][1,4]thiazepine is the crucial intermediate in the synthesis of quetiapine:

Our invention¹ relates to the process of the preparation of this intermediate. In comparison with the classical industrial method² ours offers several advantages, i.e.:

- reduction of operations number and time; - higher total yield (75% vs. 60%); - lower consumption of solvents; - reduction of waste material quantity;

All these advantages result in considerable reduction of manufacturing costs.

¹ Ł. Kaczmarek, K. Badowska-Rosłonek, E. Stolarczyk, W. Szelejewski, " Process for preparation of 11-(1-piperazinyl)dibenzo[b,f][1,4]thiazepine, an intermediate in the synthesis of the antipsychotic drug Quetiapine.", PCT/EP2004/051520 (2004).

² EP 0240228

• Legal notice:
  

  Copyright (c) Pielaszek Research, all rights reserved.
  The above materials, including auxiliary resources, are subject to Publisher's copyright and the Author(s) intellectual rights. Without limiting Author(s) rights under respective Copyright Transfer Agreement, no part of the above documents may be reproduced without the express written permission of Pielaszek Research, the Publisher. Express permission from the Author(s) is required to use the above materials for academic purposes, such as lectures or scientific presentations.
  In every case, proper references including Author(s) name(s) and URL of this webpage: https://science24.com/paper/6427 must be provided.

1. Hplc study of Cilostazol tablets: assay and release profile determination
2. Application of the new data processing method for photodiode array detector in the analysis of drug substances
3. Development and validation of the GC method for quantitative determination of semi-volatile solvents in pharmaceutical substance Bosentan
4. Validation of HPLC methods for analyzing the chemical purity of cilostazol
5. Identification of degradation products of cilostazol drug substance
6. An application of accelerator mass spectrometry (AMS) in pediatric clinical studies. Paracetamol, midazolam and spironolactone radiosynthesis and certification.
7. Development and validation of GCMS method for the control of ethyl and izopropyl methanesulphonates in pharmaceutical substance in a form of mesilate
8. Investigation of unknown impurities in cyclic dermorphin analogue by HPLC-MS
9. HPLC methods for in–process control and chemical purity determination of olopatadine
10. An improved process for the preparation of 2-amino-N-tert-butyl-2-cyanoamide hydrochlorie.
11. Analytical control of synthesis and determination of BR-S by HPLC
12. Optimization of BR-8 synthesis
13. HPLC Methods for Stress Testing of ZL-S Drug Substances
14. Method development and validation of an analytical procedure - control of residual 2-iodopropane in Latanoprost
15. The use of the hyphenated LC-MS/MS technique for the characterisation of impurity profile of Quetiapine during drug development
16. The Concept of the Central Strategic Program - Innovative Medicines
17. Zolmitriptan synthesis and in-process control by HPLC methods
18. The cytotoxic activity of glycosides of indolo[2,3-b]quinoline derivatives.
19. Disubstituted indolo[2,3-b]quinoline derivatives - the cytotoxic activity in vitro against various human tumor cell lines.
20. Mono substituted 5H- and 6H-indolo[2,3-b]quinoline derivatives and their ability to overcome the barrier of drug resistance.
21. Isolation, structural elucidation and characterization of impurities in latanoprost
22. Development of HPLC and GC methods for analysis of Zolmitriptan of pharmaceutical purity
23. Optimization of AR-3 synthesis
24. Polimorphism of Active Pharmaceutical Ingredients
25. CAN A QUEST FOR A NEW DRUG OF POLISH ORIGIN BE SUCCESSFUL?
26. ROPINIROL - GENERIC DRUG FOR PARKINSON'S DISEASE
27. CHARACTERIZATION OF ARIPIPRAZOLE SOLVATE WITH ETHANOL AND POLYMORPHIC FORMS PRODUCED DURING ITS HEATING
28. HPLC SEPARATION AND DETERMINATION OF ZIPRASIDONE
29. OPTIMIZATION OF THE CHROMATOGRAPHIC SEPARATION BY HPLC METHOD AND CONFIRMATION OF THE IDENTITY OF CHOSEN ESCITALOPRAM OXALATE INTERMEDIATE PRODUCTS
30. SYNTHESIS OF GLIMEPIRIDE - CRYSTAL STRUCTURE ANALYSIS STEP BY STEP
31. GC METHOD FOR QUANTITATIVE DETER- MINATION OF RESIDUAL 2-(2-CHLORO- ETOXY)ETHANOL (CEE) AND N-METHYL- 2-PYRROLIDINONE (NMP) IN PHARMACEU- TICAL ACTIVE SUBSTANCE
32. APPLICATION OF GC/MS FOR IDENTYFICATION OF THE SIDEPRODUCTS IN A PROCESS OF PREPARATION OF PRAMIPEXOLE.
33. THE CYTOTOXIC GLYCOSIDES OF INDOLO[2,3-B]QUINOLINE DERIVATIVES. IN VITRO AND IN VIVO STUDIES
34. MONO SUBSTITUTED 5H-INDOLO[2,3-B]- QUINOLINE DERIVATIVES AND THEIR ABILITY TO OVERCOME THE BARRIER OF DRUG RESISTANCE.
35. DISUBSTITUTED INDOLO[2,3-b]QUINOLINE DERIVATIVES. THE CYTOTOXIC ACTIVITY IN VITRO AGAINST VARIOUS HUMAN TUMOR CELL LINE.
36. SYNTHESIS OF PIOGLITAZONE HYDROCHLORIDE OF PHARMACEUTICAL PURITY AT SMALL PLANT SCALE
37. NEW IMPROVED METHOD OF POLYMORPHIC α FORM OF IMATINIB MESYLATE (GLEEVEC^®) SYNTHESIS.
38. ¹H AND ¹³C NMR DATA FOR INDOLO[2,3-b]QUINOLINES - AMINOGLYCOSIDE HYBRIDS, A NOVEL POTENT ANTICANCER DRUG FAMILY .